Daptomycin: The first approved lipopeptide antimicrobial

Consultant Pharmacist

Volumn 19, Issue 7, 2004, Pages 614-628

  Guay, David R P ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Daptomycin; Lipopeptide; LY146032

Indexed keywords

A 21978C; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; CREATINE KINASE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LINEZOLID; METICILLIN; METRONIDAZOLE; PENICILLIN G; PEPTIDOGLYCAN; VANCOMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTEREMIA; CELL MEMBRANE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SURVEILLANCE PROGRAM; DRUG SYNTHESIS; DYSPNEA; ENDOCARDITIS; GRAM POSITIVE BACTERIUM; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTENSION; INFECTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MUSCLE DISEASE; MUSCLE WEAKNESS; MYALGIA; NONHUMAN; PEPTIDE ANALYSIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; RAT; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SKIN CULTURE; STRAIN IDENTIFICATION; SYSTEMATIC REVIEW; URINARY TRACT INFECTION;

EID: 3042778065     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2004.614     Document Type: Review

References (156)

1. Bonomo RA. Multiple antibiotic-resistant bacteria in long-term-care facilities: an emerging problem in the practice of infectious diseases. Clin Infect Dis 2000;31:1414-22.
2. Bradley SF. Methicillin-resistant Staphylococcus aureus in nursing homes: epidemiology, prevention, and management. Drugs Aging 1997;10:185-98.
3. Linares J. The VISA/ GISA problem: therapeutic implications. Clin Microbiol Infect 2001;7(suppl 4):s8-s15.
4. Nicolle LE. Resistant pathogens in urinary tract infections. J Am Geriatr Soc 2002;50(7 suppl):s230-5.
5. Bonomo RA. Resistant pathogens in respiratory tract infections in older people. J Am Geriatr Soc 2002;50(7 suppl):s236-s241.
6. Norman DC. Management of antibiotic-resistant bacteria. J Am Geriatr Soc 2002; 50(7 suppl):s242-s246.
7. Debono M, Abbott BJ, Molloy RM et al. Enzymatic and chemical modifications of lipopeptide antibiotic A21978C: the synthesis and evaluation of daptomycin (LY146032). J Antibiot 1988;41:1093-105.
8. Cubicin (daptomycin £or injection) package insert. Lexington, MA: Cubist Pharmaceuticals; September 2003.
9. Allen NE, Hobbs JN Jr, Alborn WE Jr. Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY 146032. Antimicrob Agents Chemother 1987;31:1093-9.
10. Silverman JA, Oliver N, Andrew T et al. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001;45:1799-802.
11. Canepari P, Boaretti M. Lipoteichoic acid as a target for antimicrobial action. Microb Drug Resis 1996;2:85-9.
12. Boaretti M, Canepari P, del Mar Lleo M et al. The activity of daptomycin on Enterococcus faecium protoplasts: indirect evidence supporting a novel mode of action on lipoteichoic acid synthesis. J Antimicrob Chemother 1993;31:227-35.
13. Lakey JH, Ptak M. Fluorescence indicates a calcium-dependent interaction between the lipoprotein antibiotic LY146032 and phospholipid membranes. Biochemistry 1988;27:4639-45.
14. Alborn WE Jr, Allen NE, Preston DA. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother 1991;35:2282-7.
15. Allen NE, Alborn WE Jr, Hobbs JN Jr. Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrob Agents Chemother 1991;35:2639-42.
16. Canepari P, Boaretti M, del Mar Lleo M et al. Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY 146032). Antimicrob Agents Chemother 1990;34:1220-6.
17. Boaretti M, Canepari P. Identification of daptomycin-binding proteins in the membrane of Enterococcus hirae. Antimicrob Agents Chemother 1995;39:2068-72.
18. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:2538-44.
19. Laganas V, Alder J, Silverman JA. In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis. Antimicrob Agents Chemother 2003;47:2682-4.
20. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000;44:1062-6.
21. Barry AL, Fuchs PC, Brown SD. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001;45:1919-22.
22. Wise R, Andrews JM, Ashby JP. Activity of daptomycin against gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother 2001;48:563-7.
23. King A, Phillips I. The in vitro activity of daptomycin against 514 gram-positive aerobic clinical isolates. J Antimicrob Chemother 2001;48:219-23.
24. Amsterdam D, Gorzynski EA, Beam TR et al. Susceptibility of bacteraemic isolates of gram-positive cocci to daptomycin and other antimicrobial agents. J Antimicrob Chemother 1994;33:1060-4.
25. Bartoloni A, Grazia Colao M, Orsi A et al. In vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci, and Clostridium difficile. J Antimicrob Chemother 1990;26:627-33.
26. Saito H, Rolston KVI, Ho DH, LeBlanc B, Bodey GP. In-vitro activity of LY146032 against gram-positive isolates from cancer patients. J Antimicrob Chemother 1987;20:497-503.
27. Van der Auwera P, Grenier P, Klastersky J. In-vitro activity of LY146032 against Staphylococcus aureus, Listeria monocytogenes, Corynebacterium JK, and Bacillus spp., in comparison with various antibiotics. J Antimicrob Chemother 1987;20:209-12.
28. Pohlod DJ, Saravolatz LD, Somerville MM. In-vitro susceptibility of gram-positive cocci to LY146032, teicoplanin, sodium fusidate, vancomycin, and rifampicin. J Antimicrob Chemother 1987;20:197-202.
29. Huovinen P, Kotilainen P. In vitro activity of a new cyclic lipoprotein antibiotic, LY146032, against gram-positive clinical bacteria. Antmicrob Agents Chemother 1987;31:455-7.
30. Fass RJ, Helsel VL. In vitro activity of LY146032 against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother 1986;30:781-4.
31. Shonekan D, Mildvan D, Handwerger S. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD 127,391 against blood isolates of gram-positive cocci. Antimicrob Agents Chemother 1992;36:1570-2.
32. Stratton CW, Liu C, Weeks LS. Activity of LY 146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies. Antimicrob Agents Chemother 1987;31:1210-5.
33. Stratton CW, Liu C, Ratner HB, Weeks LS. Bactericidal activity of daptomycin (LY 146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies. Antimicrob Agents Chemother 1987;31:1014-6.
34. Chow AW, Chong N. In vitro activities of daptomycin (LY 146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteria. Antimicrob Agents Chemother 1988;32:788-90.
35. Petersen PJ, Bradford PA, Weiss WJ et al. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother 2002;46:2595-601.
36. Rodriguez-Tudela JL, Lopez de Felipe F, Martinez-Suarez JV et al. Comparative in-vitro activity of four peptide antibiotics against penicillin-resistant Streptococcus pneumoniae isolated from cerebrospinal fluid (CSF). J Antimicrob Chemother 1992;29:299-302.
37. Appelbaum PC, Spangler SK, Crotty E et al. Susceptibility of penicillin-sensitive and -resistant strains of Streptococcus pneumoniae to new antimicrobial agents, including daptomycin, teicoplanin, cefpodoxime, and quinolones. J Antimicrob Chemother 1989;23:509-16.
38. Dealler SF. In-vitro activity of LY146032 daptomycin and other agents against JK diphtheroids. J Antimicrob Chemother 1988;21:807-12.
39. Tankovic J, Leclercq R, Duval J. Antimicrobial susceptibility of Pediococcus spp. and genetic basis of macrolide resistance in Pediococcus acidilactici HM3020. Antimicrob Agents Chemother 1993;37:789-92.
40. Swenson JL, Facklam RR, Thornsberry C. Antimicrobial susceptibility of vancomycin-resistant Leuconostoc, Pediococcus, and Lactobacillus species. Antimicrob Agents Chemother 1990;34:543-9.
41. Chandrasekar PH, Sluchak JA. Newer agents against methicillin and/or gentamicin-resistant and -susceptible staphylococci. Chemotherapy 1989;35:333-7.
42. Knapp CC, Washington JA II. Antistaphylococcal activity of a cyclic peptide, LY 146032, and vancomycin. Antimicrob Agents Chemother 1986;30:938-9.
43. Goldstein EJC, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activities of daptomycin, vancomycin, quinupristin-dalfopristin, linezolid and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob Agents Chemother 2003;47:337-41.
44. Bingen E, Lambert-Zechovsky N, Leclercq R, Doit C, Mariani-Kurkdjian P. Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1990;26:619-26.
45. Bingen E, Doit C, Lambert-Zechovsky N et al. Bactericidal activity of daptomycin against vancomycin-resistant Enterococcus faecium in an in vitro pharmacokinetic model. Eur J Clin Microbiol Infect Dis 1991;10:1062-5.
46. Mobarakai N, Quale JM, Landman D. Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium. Antimicrob Agents Chemother 1994;38:385-7.
47. Akins RL, Rybak MJ. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide-intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob Agents Chemother 2000;44: 1925-9.
48. Duh R-W, Singh KV, Malathum K, Murray BE. In vitro activity of 19 antimicrobial agents against enterococci from healthy subjects and hospitalized patients and use of an ace gene probe from Enterococcus faecalis for species identification. Microb Drug Resis 2001; 7:39-46.
49. Jorgensen JH, Crawford SA, Kelly CC, Patterson JE. In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods. Antimicrob Agents Chemother 2003;47:3760-3.
50. Louie A, Baltch AL, Ritz WJ et al. Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci. Chemotherapy 1993;39:302-10.
51. Markowitz SM, Wells VD, Williams DS et al. Antimicrobial susceptibility and molecular epidemiology of β-lactamase producing, aminoglycoside- resistant isolates of Enterococcus faecalis. Antimicrob Agents Chemother 1991;35:1075-80.
52. Dever LL, Jorgensen JH, Barbour AG. In vitro activity of vancomycin against the spirochete Borrelia burgdorferi. Antimicrob Agents Chemother 1993;37:1115-21.
53. Akins RL, Rybak MJ. Bactericidal activities of two daptomycin regimens against clinical mains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2001;45:454-9.
54. Coudron PE, Johnston JL, Archer GL. In-vitro activity of LY146032 against Staphylococcus aureus and S. epidermidis. J Antimicrob Chemother 1987;20:505-11.
55. Benson CA, Beaudette F, Trenholme G. Comparative in-vitro activity of LY146032, a new peptolide, with vancomycin and eight other agents against gram-positive organisms. J Antimicrob Chemother 1987;20:191-6.
56. Ehlert F, Neu HC. In vitro activity of LY146032 (daptomycin), a new peptolide. Eur J Clin Microbiol 1987;6:84-90.
57. Machka K, Braveny I. Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci. Eur J Clin Microbiol 1987;6:96-9.
58. Blenkharn JI, Darrell JH. Comparative in vitro activity of daptomycin (LY146032) and vancomycin against gram-positive cocci determined using a pharmacokinetic model. Eur J Clin Microbiol 1989;8:734-7.
59. Verbist L. In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci. Antimicrob Agents Chemother 1987;31:340-2.
60. +2 and albumin on these drugs. Antimicrob Agents Chemother 1991;35:1710-6.
61. Wanger AR, Murray BE. Activity of LY 146032 against enterococci with and without high-level aminoglycoside resistance, including two penicillinase- producing strains. Antimicrob Agents Chemother 1987;31:1779-81.
62. Flandrois JP, Fardel G, Carret G. Early stages of in vitro killing curve of LY 146032 and vancomycin for Staphylococcus aureus. Antimicrob Agents Chemother 1988;32: 454-7.
63. Cha R, Grucz RG Jr, Rybak MJ. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother 2003;47:1598-1603.
64. Lentino JR, Strodthman R. Comparison of in vitro activity of daptomycin, vancomycin, and fluoroquinolones in broth and serum against Staphylococcus epidermidis as determined by time-kill kinetics. Chemotherapy 1989;35:168-73.
65. Schwalbe RS, Ritz WJ, Verma PR et al. Selection for vancomycin resistance in clinical isolates of Staphylococcus haemolyticus. J Infect Dis 1990;161:45-51.
66. Jorgensen JA, Maher LA, Redding JS. In vitro activity of LY 146032 (daptomycin) against selected aerobic bacteria. Eur J Clin Microbiol 1987;6:91-6.
67. Snydman DR, Jacobus NV, McDermott LA et al. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob Agents Chemother 2000;44:3447-50.
68. Fontana R, Grossato A, Ligozzi M et al. In vitro response to bactericidal activity of cell-wall active antibiotics does not support the general opinion that enterococci are naturally tolerant to these antibiotics. Antimicrob Agents Chemother 1990;34:1518-22.
69. Pankuch GA, Jacobs MR, Appelbaum PC. Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobials. J Antimicrob Chemother 2003;51:443-6.
70. Nap E, Werner H, Heizmann W. In vitro activity of daptomycin- metronidazole combinations against mixed bacterial cultures: reduced activity of metronidazole against Bacteroides species in the presence of Enterococcus faecalis. Eur J Clin Microbiol Infect Dis 1990;9:287-91.
71. Blaser J, Vergeres P, Widmer AF et al. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob Agents Chemother 1995;39:1134-9.
72. Griffiths JK, Daly JS, Dodge RA. Two cases of endocarditis due to Lactobacillus species: antimicrobial susceptibility, review, and discussion of therapy. Clin Infect Dis 1992;15:250-5.
73. Watanakunakorn C. In-vitro activity of LY146032, a novel cyclic lipopeptide, alone and in combination with gentamicin or tobramycin against enterococci. J Antimicrob Chemother 1987;19:445-8.
74. Miniter PM, Patterson TF, Johnson MA, Andriole VT. Activity of LY146032 in vitro and in experimental pyelonephritis. Antimicrob Agents Chemother 1987;31:1199-203.
75. Debbia E, Pesce A, Schito GC. In vitro activity of LY 146032 alone and in combination with other antibiotics against gram-positive bacteria. Antimicrob Agents Chemother 1988;32:279-81.
76. Van der Auwera P. Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY 146032) combined or not combined with amikacin compared with those of vancomycin. Antimicrob Agents Chemother 1989;33:1783-90.
77. Bush LM, Boscia JA, Wendeler M, Pitsakis PG, Kaye D. In vitro postantibiotic effect of daptomycin (LY 146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 1989;33:1198-200.
78. Pankuch GA, Jacobs MR, Appelbaum PC. Postantibiotic effects of daptomycin against 14 staphylococcal and pneumococcal clinical isolates. Antimicrob Agents Chemother 2003;47:3012-4.
79. Lamp KC, Rybak MJ, Bailey EM, Kaatz GW. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob Agents Chemother 1992;36:2709-14.
80. Lamp KC, Rybak MJ. Teicoplanin and daptomycin bactericidal activities in the presence of albumin or serum under controlled conditions of pH and ionized calcium. Antimicrob Agents Chemother 1993;37:605-9.
81. Pascual A, Ramirez de Arellano E, Martinez LM et al. Effect of polyurethane catheters and bacterial biofilms on the in-vitro activity of antimicrobials against Staphylococcus epidermidis. J Hosp Infect 1993;24:211-8.
82. Gristina AG, Jennings RA, Naylor PT et al. Comparative in vitro antibiotic resistance of surface-colonizing coagulase-negative staphylococci. Antimicrob Agents Chemother 1989;33:813-6.
83. Naylor PT, Myrvik QN, Gristina A. Antibiotic resistance of biomaterial-adherent coagulase-negative and coagulase-positive staphylococci. Clin Orthoped 1990;261: 126-33.
84. Andrew JA, Wale MCJ, Wale LJ, Greenwood D. The effect of cultural conditions on the activity of LY146032 against staphylococci and streptococci. J Antimicrob Chemother 1987;20:213-21.
85. Bryant RE, Mazza JA, Gardner EM. Effect of abscess milieu on bactericidal activity of LY146032 against staphylococci. Eur J Clin Microbiol 1987;6:186-8.
86. Marone P, Perversi L, Navarra A et al. Activity of daptomycin against enterococci and coagulase-negative staphylococci (CNS): relationship between CNS susceptibility and slime production. J Chemother 1993;5: 151-4.
87. Hermsen ED, Hovde LB, Hotchkiss JR et al. Increasing killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysis model. Antimicrob Agents Chemother 2003;47:3764-7.
88. Liebowitz LD, Saunders J, Chalkley LJ et al. In vitro selection of bacteria resistant to LY 146032, a new cyclic lipopeptide. Antimicrob Agents Chemother 1988;32:24-6.
89. Mouton RP, Mulders SLTM. LY146032: activity and resistance development in vitro. J Antimicrob Chemother 1987;20:513-7.
90. nd Interscience Conference on Antimicrobial Agents and Chemotherapy; San Diego, CA; September 27-30, 2002 (abstract D-37).
91. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003;47:1318-23.
92. Wise R, Gee T, Andrews JM, Dvorchik B, Marshall G. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother 2002;46:31-3.
93. Woodworth JR, Nyhart EH, Wolny JD et al. Tobramycin and daptomycin disposition when co-administered to healthy volunteers. J Antimicrob Chemother 1994;33:655-9.
94. Pryka RD, Novak RM, Wagner DK et al. Clinical pharmacokinetics of daptomycin. DICP Ann Pharmacother 1990;24:255-6.
95. Lee BL, Sachdeva M, Chambers HF. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob Agents Chemother 1991;35:2505-8.
96. Rybak MJ, Bailey EM, Lamp KC, Kaatz GW. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob Agents Chemother 1992;36:1109-14.
97. Woodworth JR, Nyhart EH Jr, Brier GL, Wolny JD, Black HR. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 1992;36:318-325.
98. Rybak MJ, Albrecht LM, Berman JR, Warbasse LH, Svensson CK. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 1990;34:792-795.
99. Rybak MJ, Lerner SA, Levine DP et al. Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis. Antimicrob Agents Chemother 1991;35:696-700.
100. th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; Houston, TX; September 17-19, 1989 (abstract 1345).
101. th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; Houston, TX; September 17-19, 1989 (abstract 1346).
102. st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL; September 29-October 2, 1991 (abstract 1302).
103. th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; Houston, TX; September 17-19, 1989 (abstract 1347).
104. Van der Auwera P, Matsumoto T, Husson M. Intraphagocytic penetration of antibiotics. J Antimicrob Chemother 1988;22:185-92.
105. th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; New Orleans, LA; September 28-October 1, 1986 (abstract 894).
106. th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; Los Angeles, CA; October 23-26, 1988 (abstract 125).
107. nd Interscience Conference on Antimicrobial Agents and Chemotherapy; San Diego, CA; September 27-30, 2002 (abstract A-1387).
108. rd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL; September 14-17, 2003 (abstract A-26).
109. Sakoulas G, Eliopoulos GM, Alder J, Thauvin-Eliopoulos C. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:1714-8.
110. Vaudaux P, Francois P, Bisognano C, Li D, Lew DP, Schrenzel J. Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. J Antimicrob Chemother 2003;52:89-95.
111. Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2001;45:845-51.
112. Kephart P, Esposito AL. Comparison of the investigational drug, LY146032, with vancomycin in experimental pneumonia due to methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1988;21:33-9.
113. Nord CE, Lindmark A, Persson I. LY146032 treatment of Clostridium difficile colitis in hamsters. Eur J Clin Microbiol 1987;6:686.
114. Luu QN, Buxton TB, Nelson DR, Rissing JP. Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin. Eur J Clin Microbiol 1989;8:562-3.
115. Verghese A, Haire C, Franzus B, Smith K. LY146032 in a hamster model of Staphylococcus aureus pneumonia-effect on in vivo clearance and mortality and in vitro opsonophagocytic killing. Chemotherapy 1988;34:497-503.
116. Smith K, Cobbs G, Dill R, Lyon D, Graves A, Avent K. Daptomycin versus vancomycin treatment for Staphylococcus aureus bacteremia in a murine model. Chemotherapy 1990;36:428-34.
117. Voorn GP, Kuyvenhoven J, Goessens WHF, et al. Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin. Antimicrob Agents Chemother 1994;38:487-93.
118. Michiels M-J, Bergeron MG. Differential increased survival of staphylococci and limited ultrastructural changes in the core of infected fibrin clots after daptomycin administration. Antimicrob Agents Chemother 1996;40: 203-11.
119. Eliopoulos GM, Willey S, Reizner E, Spitzer PG, Caputo G, Moellering RC Jr. In vitro and in vivo activity of LY146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother 1986;30:532-5.
120. Ramos MC, Grayson ML, Eliopoulos GM, Bayer AS. Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococci. Antimicrob Agents Chemother 1992;36:1864-9.
121. Kennedy S, Chambers HF. Daptomycin (LY 146032) for prevention and treatment of experimental aortic valve endocarditis. Antimicrob Agents Chemother 1989;33:1522-5.
122. Haworth CS, Sobieski MW, Scheld WM, Park TS. Staphylococcus aureus ventriculitis treated with single-dose intraventricular vancomycin or daptomycin (LY 146032): bacterial and antibiotic kinetics in hydrocephalic rabbits. Antimicrob Agents Chemother 1990;34:245-51.
123. Kaatz GW, Seo SM, Reddy VN, Bailey EM, Rybak MJ. Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1990;34:2081-5.
124. Cantoni L, Glauser MP, Bille J. Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob Agents Chemother 1990;34:2348-53.
125. Bayer AS, Yih J, Hirano L. LY 146032 compared with penicillin G in experimental aortic valve endocarditis caused by group G streptococci. Antimicrob Agents Chemother 1988;32: 141-3.
126. Wheat LJ, Smith JW, Reynolds J, Bemis AT, Treger T, Norton JA. Comparison of cefazolin, cefamandole, vancomycin, and LY 146032 for prophylaxis of experimental Staphylococcus epidermidis endocarditis. Antimicrob Agents Chemother 1988;32:63-7.
127. Sapico FL, Ginunas VJ, Canawati HN, Montgomerie JZ. LY 146032, alone and in combination with gentamicin, for the treatment of enterococcal pyelonephritis in the rat model. Antimicrob Agents Chemother 1988;32:81-3.
128. Bush LM, Boscia JA, Kaye D. Daptomycin (LY146032) treatment of experimental enterococcal endocarditis. Antimicrob Agents Chemother 1988;32:877-81.
129. Mader JT, Adams K. Comparative evaluation of daptomycin (LY 146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother 1989;33:689-92.
130. Wood CA, Finkbeiner HC, Kohlhepp SJ, Kohnen PW, Gilbert DN. Influence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicity. Antimicrob Agents Chemother 1989;33:1280-5.
131. Hindes RG, Willey SH, Eliopoulos GM, et al. Treatment of experimental endocarditis caused by a β-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother 1989;33:1019-22.
132. Smith K, Cobbs G, Dill R, Lyon D, Graves A, Avent K. Daptomycin versus vancomycin treatment for Staphylococcus aureus bacteremia in a murine model. Chemotherapy 1990;36:428-34.
133. Dong M-Y, Chang T-W, Gorbach SL. Treatment of Clostridium difficile colitis in hamsters with a lipopeptide antibiotic, LY 146032. Antimicrob Agents Chemother 1987;31:1135-6.
134. Golan Y, Poutsiaka DD, Tozzi S et al. Daptomycin for line-related Leuconostoc bacteraemia. J Antimicrob Chemother 2001;47: 364-5 (letter).
135. Garrison MW, Rotschafer JC, Crossley KB. Suboptimal effect of daptomycin in the treatment of bacteremias. South Med 1989;82:1414-5.
136. th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; Los Angeles, CA; October 23-26, 1988 (abstract 932).
137. st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL; September 29-October 2, 1991 (abstract 885).
138. Tally FP, DeBruin MF. Development of daptomycin for gram-positive infections. J Antimicrob Chemother 2000;46:523-6.
139. st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL; September 22-25, 2001 (abstract L-1482).
140. Campanaro ES, Tally FP, Eisenstein BI, Arbeit RD. Comparison of efficacy and safety of daptomycin (DAP) versus semisynthetic penicillin (SSP) and vancomycin (VAN) in patients with complicated skin and skin structure infections (cSSSI). Proceedings of the 43rd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL; September 14-17, 2003 (abstract L-737).
141. Kuechle DK, Landon GC, Musher DM, Noble PC. Elution of vancomycin, daptomycin, and amikacin from acrylic bone cement. Clin Orthoped 1991;264:302-8.
142. Oleson FB Jr, Berman CL, Kirkpatrick JB et al. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000;44:2948-53.
143. Kreft B, de Wit C, Krech R et al. Experimental studies on nephrotoxicity and pharmacokinetics of LY 146032 (daptomycin) in rats. J Antimicrob Chemother 1990;25:635-43.
144. Thibault N, Grenier L, Simard M, Bergeron MG, Beauchamp D. Protection against gentamicin nephrotoxicity by daptomycin in nephrectomized rats. Life Sci 1995;56:1877-87.
145. Thibault N, Grenier L, Simard M et al. Attenuation by daptomycin of gentamicin-induced experimental nephrotoxicity. Antimicrob Agents Chemother 1994;38:1027-35.
146. Beauchamp D, Pellerin M, Gourde P et al. Effects of daptomycin and vancomycin on tobramycin nephrotoxicity in rats. Antimicrob Agents Chemother 1990;34:139-47.
147. Couture M, Simard M, Gourde P et al. Daptomycin may attenuate experimental tobramycin nephrotoxicity by electrostatic complexation to tobramycin. Antimicrob Agents Chemother 1994;38:742-9.
148. Tawfik AF. Effects of vancomycin, teicoplanin, daptomycin and coumermycin on normal immune capabilities. J Chemother 1991;3:226-31.
149. Schubert S, Ullmann U. Influence of Ly146032 on chemotaxis, chemiluminescence of PMN and lymphocyte transformation in vitro. Infection 1989;17:374-7.
150. Van der Auwera P, Petrikkos G, Matsumoto T et al. Influence of LY146032 on human polymorphonuclear leucocytes in vitro. J Antimicrob Chemother 1988;21:57-63.
151. Van der Auwera P, Husson M. Influence of antibiotics on motility and adherence of human neutrophils studied in vitro. Drugs Expt Clin Res 1989;15:211-8.
152. Tripodi M-F, Adinolfi LE, Utili R et al. Influence of subinhibitory concentrations of loracarbef (LY 163892) and daptomycin (LY 146032) on bacterial phagocytosis, killing and serum sensitivity. J Antimicrob Chemother 1990;26:491-501.
153. Critchley IA, Blosser-Middleton RS, Jones ME, Thornsberry C, Sahm DF, Karlowsky JA. Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001. Antimicrob Agents Chemother 2003;47:1689-93.
154. Critchley IA, Draghi DC, Sahm DF et al. Activity of daptomycin against susceptible and multidrug-resistant gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J Antimicrob Chemother 2003;51:639-49.
155. Richter SS, Kealey DE, Murray CT et al. The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother 2003;52:123-7.
156. Restrepo MI, Velez JA, McElmeel ML et al. Activity of daptomycin against recent North American isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2003;47:2974-7.